Actively Recruiting
Evaluating Safety, Dosing, and Activity of JMBI-001 Tablets in Adults With MYC-Positive Advanced Solid Tumors or Non-Hodgkin Lymphoma
Led by Chengdu Anticancer Bioscience, Ltd. · Updated on 2026-10-15
150
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating JMBI-001, an oral drug, for adults with MYC-positive advanced cancers, including solid tumors and non-Hodgkin lymphoma. This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of JMBI-001, and to determine the recommended doses for further study phases. The trial includes patients whose cancers have progressed despite standard treatments or are not treatable by standard methods. Participants will take JMBI-001 orally once daily on an empty stomach for 4 consecutive days, followed by 3 days without treatment. This 7-day cycle repeats three times to complete a 21-day treatment cycle. Treatment continues until specific criteria require stopping or withdrawal. The study evaluates dosing in phases, starting with dose escalation to find the maximum tolerated dose, followed by dose expansion and efficacy assessment in selected tumor types. Throughout the study, participants will visit the study site regularly for medical interviews, physical exams, blood tests, electrocardiograms, and imaging to monitor their health and response to treatment. Researchers will monitor safety, adverse events, drug levels in the blood, and tumor response using standardized criteria. Participation may last up to about 24 months for efficacy assessments and includes close follow-up for side effects and treatment effects.
CONDITIONS
Brief Title
Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers
Research Team
C
Clinical Trial Information Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here